Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends

Posa, Alessandro; Contegiacomo, Andrea; Ponziani, Francesca Romana; Punzi, Ernesto; Mazza, Giulia; Scrofani, Anna Rita; Pompili, Maurizio; Goldberg, S. Nahum; Natale, Luigi; Gasbarrini, Antonio; Sala, Evis; Iezzi, Roberto

doi:10.3390/ijms24087344

Cited by 1 publication

(1 citation statement)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, there are many factors that lead to the lack of synergistic effect between cryoablation and PD-1 inhibitors in this study, and further studies are required. Additionally, it is worth noting that some studies have demonstrated that thermal ablation can promote the release of tumor antigens, thereby driving downstream immune responses (32)(33)(34). The differences in the effects of different ablation methods such as thermal ablation or cryoablation on antitumor immunity are also worth further research.…”

Section: Discussionmentioning

confidence: 99%

Argon-helium knife cryoablation plus programmed cell death protein 1 inhibitor in the treatment of advanced soft tissue sarcomas: there is no evidence of the synergistic effects of this combination therapy

Wang,

Zong,

Dong

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundEffective treatment for advanced soft tissue sarcomas (STSs) is necessary for improved outcomes. Previous studies have suggested that cryoablation can have a synergistic effect with programmed cell death protein-1 (PD-1) inhibitor in the treatment of malignancy. This study aimed to clarify the efficacy and safety of argon-helium knife cryoablation in combination with PD-1 inhibitor in the treatment of STSs.MethodsRetrospectively collected and analyzed the clinical data of patients with advanced STS who underwent cryoablation and PD-1 inhibitor between March 2018 and December 2021.ResultsThis study included 27 patients with advanced STS. In terms of target lesions treated with cryoablation, 1 patient achieved complete response, 15 patients had partial response (PR), 10 patients had stable disease, and 1 patient had progressive disease. This corresponded to an overall response rate of 59.3% and a disease control rate of 96.3%. In terms of distant target lesions untreated with cryoablation, only two patients had a PR compared to the diameter of the lesion before ablation. The combination therapy was relatively well tolerated. None of the patients experienced treatment-related death or delayed treatment due to adverse events.ConclusionCryoablation combined with PD-1 inhibitors in the therapy of advanced STS is safe and can effectively shrink the cryoablation-target lesion. However, there is no evidence of the synergistic effects of this combination therapy.

show abstract

Section: Discussionmentioning

confidence: 99%